InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year

Reports FY25 revenue $4.9M vs $4.6M last year. The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. Eric Adams, InMed Chief Executive Officer, commented, “Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901’s potential as a small-molecule drug candidate that addresses Alzheimer’s disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer’s pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification.”